EVAR非全身麻醉的系统综述与荟萃分析:临床结局与证据稳健性
非全身麻醉与30天死亡率降低无显著关联(RR 0.90,95%CI 0.54-1.52),但证据稳健性受单研究影响大,GRADE证据确定性极低。
要点
- 非全身麻醉不增加EVAR术后30天死亡风险,但也不证明优于全身麻醉。
- 非全身麻醉与住院时间轻度缩短相关(平均差-0.53天)。
- 当前观察性证据支持个体化麻醉选择,而非两种技术等效或优劣。
核心结论
- 非全身麻醉用于EVAR不增加30天死亡风险,但生存估计对研究特征和手术复杂度敏感。
- 现有观察性证据支持个体化麻醉选择,不能证明任一技术优越或等效。
研究设计与样本
- 系统综述与荟萃分析,纳入2015-2025年比较性观察研究,检索PubMed、MEDLINE、Embase和Scopus。
- 主要结局为30天和住院死亡率,次要结局包括住院时间和术后并发症。
- 采用随机效应模型(Paule-Mandel估计量、Hartung-Knapp调整)、预测区间和预设影响诊断。
主要发现
- 非全身麻醉与全身麻醉相比,30天死亡率无显著差异(RR 0.90,95%CI 0.54-1.52;I2≈86%;预测区间宽)。
- 影响诊断识别出一项影响性研究,排除后非全身麻醉死亡率更低(RR 0.72,95%CI 0.59-0.87;I2≈1%)。
- 非全身麻醉与住院时间轻度缩短相关(平均差-0.53天,95%CI -1.02至-0.03)。
- ICU停留时间或主要并发症方面未观察到一致差异。
- 总体证据确定性经GRADE评定为极低。
关键数值与推荐
- 30天死亡率:非全身麻醉 vs 全身麻醉,RR 0.90(95%CI 0.54-1.52;I2≈86%)。
- 排除一项影响性研究后30天死亡率:RR 0.72(95%CI 0.59-0.87;I2≈1%)。
- 住院时间平均差:-0.53天(95%CI -1.02至-0.03)。
- GRADE证据确定性:极低。
临床怎么用
- 非全身麻醉可作为EVAR的合理选择之一,不增加30天死亡风险。
- 麻醉策略应个体化,综合考虑患者特征和手术复杂度。
- 需向患者说明现有证据确定性极低,两种技术优劣未定。
局限性
- 仅纳入观察性研究,存在选择偏倚和混杂可能。
- 30天死亡率合并估计异质性高(I2≈86%),且受单项研究影响大。
- GRADE证据确定性极低,限制结论强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal anesthetic strategy for endovascular aortic aneurysm repair (EVAR) remains debated. While recent meta-analyses suggested potential benefits for non-general anesthesia (Non-GA), available evidence is observational, and the robustness of pooled estimates remains uncertain. METHODS: A systematic review and meta-analysis of comparative observational studies (2015-2025) was conducted across PubMed, MEDLINE, Embase, and Scopus. Primary outcomes were 30-day and in-hospital mortality. Secondary outcomes included length of stay (LOS) and postoperative complications. Random-effects models utilized the Paule-Mandel estimator with Hartung-Knapp adjustment, prediction intervals, and prespecified influence diagnostics. RESULTS: Twenty-two studies comprising >150,000 EVAR procedures were analyzed. Non-GA was not associated with reduced 30-day mortality compared with general anesthesia (RR 0.90, 95% CI 0.54-1.52; I2≈86%; wide prediction interval). Influence diagnostics identified one influential study; its exclusion yielded a lower mortality for Non-GA (RR 0.72, 95% CI 0.59-0.87; I2≈1%). Non-GA was associated with a modest reduction in hospital LOS (mean difference -0.53 days, 95% CI -1.02 to -0.03), but no consistent differences were observed in ICU stay or major complications. The overall certainty of evidence was judged very low (GRADE). CONCLUSIONS: Non-GA for EVAR does not increase 30-day mortality risk compared to general anesthesia. However, survival estimates are sensitive to study-level characteristics and procedural complexity. Current observational evidence supports individualized anesthetic selection rather than proving superiority or equivalence of either technique.
引用
- Nisi F, Piscopo R, Aurelli F, et al. Non-General Anesthesia for Endovascular Aneurysm Repair: A Systematic Review and Meta-analysis of Clinical Outcomes and Robustness of Evidence. Ann Vasc Surg. 2026. PMID: 42874859. doi:10.1016/j.avsg.2026.09.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。